Grail shares fell after its Galleri blood test failed a key UK study's primary endpoint. Despite the setback, Baird and Canaccord maintained bullish ratings but lowered price targets to $82 and $80 respectively. Both analysts view the broader data set constructively and believe the market's negative reaction to the trial news is overdone.